21 results
8-K
EX-99.1
NRIX
Nurix Therapeutics Inc
7 Apr 22
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update
4:08pm
in the Phase 1 trial of DeTIL-0255, Nurix’s drug-enhanced tumor infiltrating lymphocyte (TIL) program
Awarded Innovation Passport for Entry into Innovative … to a patient. It also represents the first application of targeted protein modulation in the field of cell therapy.
Awarded Innovation Passport for NX
DRS
EX-4.2
ys64nn4otu w9cu9
5 May 20
Draft registration statement
12:00am
S-1
EX-4.2
l8c1d2b
2 Jul 20
IPO registration
4:04pm
10-K
5ixat8so2uf
16 Feb 21
Annual report
4:11pm
DRS/A
9bqq3
10 Jun 20
Draft registration statement (amended)
12:00am
424B4
xe1up
24 Jul 20
Prospectus supplement with pricing info
4:06pm
S-1/A
c2sc7vq581jvtckxkk
20 Jul 20
IPO registration (amended)
6:32am
S-1
h9f59r7m3 jw
2 Jul 20
IPO registration
4:04pm
DRS
sptwifg
5 May 20
Draft registration statement
12:00am
S-1/A
EX-10.3
q6pmt3ay7n7
20 Jul 20
IPO registration (amended)
6:32am